Yazar "Sereflican, Betul" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Halo Phenomenon With an Unusual Involvement: Bilateral Halo Nipple
    (Amer Medical Assoc, 2010) Goksugur, Nadir; Sereflican, Betul; Goksugur, Sevil Bilir
  • Küçük Resim Yok
    Öğe
    Insights into chest computed tomography findings in Behcet's disease
    (Turkish Assoc Tuberculosis & Thorax, 2018) Kizildag, Betul; Yurttutan, Nursel; Sarica, Mehmet Akif; Atilla, Nurhan; Baykara, Murat; Sereflican, Betul; Yildirim Cetin, Gozde
    Introduction: To evaluate the spectrum and frequency of abnormal chest multidedector computed tomography (MDCT) findings in Behcet's disease(BD). Materials and Methods: Chest MDCT scans of 44 patients referred to radiology department for chest symptoms those had prior or newly established diagnosis of BD between 2009-2016 were retrospectively reviewed. Abnormal findings within pulmonary artery (PA), lungs, other large vessels, heart, mediastinum, pleura and pericardium were noted. Results: Sixteen patients had one ore more computed tomography (CT) findings related to BD. PA involvement was most common (27.2%) presentation revealing thrombosis in 8 and aneurysms in 4 of 12 patients. Mean PA diameter was 29 +/- 3.7 mm. Patients with PA involvement had significantly higher PA diameters than those without (p< 0.001). Hypertrophied bronchial artery seen as serpiginous vessels around hilum was a common finding (66.6%). Lung parenchyma findings was rarely isolated and usually associated with PA involvement with subpleural alveolar opacities, focal atelectasis and ill-defined nodular opacities. Cardiac filling defects were accompanying lesions in most of patients with PA aneurysms (75%). Conclusion: BD is associated with a wide spectrum of simultaneous involvement of discrete anatomical sites. PA enlargement and hypertrophied bronchial artery is a clue for patients with PA involvement. Heart chambers should be checked for filling defects particularly in patients with PA aneurysms.
  • Küçük Resim Yok
    Öğe
    Serum visfatin, adiponectin, and tumor necrosis factor alpha (TNF-?) levels in patients with psoriasis and their correlation with disease severity
    (Croatian Dermatovenerological Society, 2016) Sereflican, Betul; Goksugur, Nadir; Bugdayci, Guler; Polat, Mualla; Parlak, Ali Haydar
    Psoriasis is a chronic, autoimmune, and inflammatory disease of unknown etiology, characterized by T lymphocyte mediated keratinocyte proliferation. In recent years the relationship between psoriasis and adipose tissue cytokines has been reported. Psoriasis as a triggering factor for the immune and metabolic disorders can be associated with diabetes mellitus, abnormal lipid metabolism, and metabolic syndrome. In this study we assessed the adipose tissue cytokines visfatin, adiponectin, and tumor necrosis factor-? (TNF-?) levels in psoriasis patients and evaluated the relationship between disease severity and cytokines. The study included 42 patients with psoriasis and 42 healthy individuals. Visfatin, adiponectin, and TNF-? levels were measured in both the psoriasis and the control group. The disease severity index was assessed in psoriatic patients by means of PASI. The relationship between visfatin, adiponectin, TNF-?, PASI score, and obesity was evaluated. When serum TNF-?, adiponectin, and visfatin levels of the patient group were compared with those of the control group, the TNF-? levels were statistically higher (p = 0.00) and the adiponectin levels were statistically lower (p = 0.024). The visfatin levels were higher in the psoriatic patients compared to the control group, but this difference was not statistically significant (p = 0.73). The relationship between PASI-TNF-? and between PASI-adiponectin was statistically significant (p = 0.009 and p = 0.004). A positive correlation was observed between body mass index (BMI) and visfatin (p = 0.031). These results indicate that TNF-? and adiponectin play a part in psoriasis etiopathogenesis and can be used as parameters to evaluate the severity of the disease. However, the role of visfatin in psoriasis pathogenesis is unclear. Further clinical studies are needed to clarify the effect of visfatin in psoriatic patients. © 2016, Croatian Dermatovenerological Society. All rights reserved.